Literature DB >> 9083788

Binding characteristics of gamma-hydroxybutyric acid as a weak but selective GABAB receptor agonist.

P Mathivet1, R Bernasconi, J De Barry, C Marescaux, H Bittiger.   

Abstract

The aim of this study was to reexamine the concept that gamma-hydroxybutyric acid (GHB) is a weak but selective agonist at gamma-aminobutyric acidB (GABAB) receptors, using binding experiments with several radioligands. Ki values of GHB were similar (approximately equal to 100 microM) in three agonist radioligand assays for GABAB receptors, [3H]baclofen (beta-para-chlorophenyl-gamma-aminobutyric acid), [3H]CGP 27492 (3-aminopropyl-phosphinic acid) and [3H]GABA, in the presence of the GABAA receptor agonist isoguvacine with rat cortical, cerebellar and hippocampal membranes. In competition experiments between GHB and the GABAB receptor antagonist, [3H]CGP 54626 (3-N [1-{(S)-3,4-dichlorophenyl}-ethylamino]-2-(S)-hydroxypropyl cyclo-hexylmethyl phosphinic acid), the IC50 values were significantly increased with 300 microM of 5'-guanyl-imidodiphosphate (Gpp(NH)p), which suggested that guanine nucleotide binding proteins (G-proteins) modulate GHB binding on GABAB receptors. The inhibition by GHB of [3H]CGP 27492 binding in cortical membranes was not altered in the presence of 0.3 or 3 mM of the two GHB dehydrogenase inhibitors, valproate and ethosuximide. Thus, GHB is not reconverted into GABA by GHB dehydrogenase. Taken together, the results of this study demonstrated that GHB is an endogenous weak but selective agonist at GABAB receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9083788     DOI: 10.1016/s0014-2999(96)00916-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  34 in total

1.  GABAB receptor-positive modulators: brain region-dependent effects.

Authors:  Julie G Hensler; Tushar Advani; Teresa F Burke; Kejun Cheng; Kenner C Rice; Wouter Koek
Journal:  J Pharmacol Exp Ther       Date:  2011-09-27       Impact factor: 4.030

2.  Effects of the GABAB receptor-positive modulators CGP7930 and rac-BHFF in baclofen- and γ-hydroxybutyrate-discriminating pigeons.

Authors:  Wouter Koek; Charles P France; Kejun Cheng; Kenner C Rice
Journal:  J Pharmacol Exp Ther       Date:  2012-02-07       Impact factor: 4.030

3.  Brain uptake of the drug of abuse γ-hydroxybutyric acid in rats.

Authors:  Samuel A Roiko; Melanie A Felmlee; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2011-10-21       Impact factor: 3.922

4.  Behavioral effects of gamma-hydroxybutyrate, its precursor gamma-butyrolactone, and GABA(B) receptor agonists: time course and differential antagonism by the GABA(B) receptor antagonist 3-aminopropyl(diethoxymethyl)phosphinic acid (CGP35348).

Authors:  Wouter Koek; Susan L Mercer; Andrew Coop; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2009-06-29       Impact factor: 4.030

5.  Sodium oxybate: a potential new pharmacological option for the treatment of fibromyalgia syndrome.

Authors:  Todd J Swick
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-08       Impact factor: 5.346

6.  gamma-Hydroxybutyric acid poisoning.

Authors:  S R Williams
Journal:  West J Med       Date:  1998-03

7.  GABAB receptor-positive modulators: enhancement of GABAB receptor agonist effects in vivo.

Authors:  Wouter Koek; Charles P France; Kejun Cheng; Kenner C Rice
Journal:  J Pharmacol Exp Ther       Date:  2010-07-13       Impact factor: 4.030

8.  Metabolomic study of polyamines in rat urine following intraperitoneal injection of γ-hydroxybutyric acid.

Authors:  Hyeon-Seong Lee; Chan Seo; Young-A Kim; Meejung Park; Boyeon Choi; Moongi Ji; Sooyeun Lee; Man-Jeong Paik
Journal:  Metabolomics       Date:  2019-04-02       Impact factor: 4.290

9.  Behavioral effects of gamma-hydroxybutyrate in humans.

Authors:  Alison Oliveto; William Brooks Gentry; Rhonda Pruzinsky; Kishorchandra Gonsai; Thomas R Kosten; Bridget Martell; James Poling
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

10.  Comparative abuse liability of GHB and ethanol in humans.

Authors:  Matthew W Johnson; Roland R Griffiths
Journal:  Exp Clin Psychopharmacol       Date:  2013-02-18       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.